Congenital Malformation of the Circulatory System (including Heart Defects) — Clinical Documentation Guide (2026)

This Clinical Documentation Guide (CDG) provides AAPC/AHIMA-credentialed coders and CDI specialists with comprehensive coding, clinical, and documentation guidance for congenital malformations of the circulatory system, including congenital heart defects (CHD), classified under ICD-10-CM FY2026 categories Q20–Q28. Content reflects the FY2026 ICD-10-CM Official Guidelines effective October 1, 2025 through September 30, 2026, and incorporates current CPT (CY2026), MS-DRG v43, HCC v28 risk adjustment, and evidence-based CDI query practices. Use this guide to ensure accurate congenital cardiac diagnosis code assignment, appropriate CDI triggers, defensible documentation across all care settings, and optimal risk adjustment capture throughout the patient’s lifetime.

🔍 1. Definition

Congenital malformations of the circulatory system are structural abnormalities of the heart and great vessels that arise during fetal development, present at birth, and are classified within ICD-10-CM categories Q20–Q28. The spectrum ranges from minor lesions (e.g., small muscular ventricular septal defects that close spontaneously) to life-threatening critical defects requiring immediate neonatal intervention. According to the CDC, congenital heart defects (CHD) are the most common type of birth defect, occurring in approximately 1 in 100 live births in the United States—roughly 40,000 births per year.

Congenital heart disease specifically refers to structural malformations of the cardiac chambers, septa, valves, and great vessels resulting from abnormal embryologic cardiovascular development. These include defects of the cardiac septa (Q20–Q21), valvular malformations (Q22–Q23), other cardiac anomalies (Q24), great artery defects (Q25), great vein anomalies (Q26), and peripheral vascular malformations (Q27–Q28), as defined by the American Heart Association.

Critical congenital heart disease (CCHD) refers to the subset of CHD requiring catheter or surgical intervention in the first year of life. The seven classic “CCHD” lesions include hypoplastic left heart syndrome (HLHS), pulmonary atresia, tetralogy of Fallot, total anomalous pulmonary venous return, transposition of the great arteries, tricuspid atresia, and truncus arteriosus.

Coding permanence: Per ICD-10-CM Official Coding Guidelines, Chapter 17, codes from Q00–Q99 may be used throughout the life of the patient if the condition is still clinically present. Once a defect has been fully corrected and is no longer clinically active, assign Z87.74 (Personal history of corrected congenital malformations of heart and circulatory system). If the condition has been addressed but not fully corrected—or if residual effects persist—the Q code remains appropriate.

🗂️ 2. Alternative Terminology

Clinicians, surgeons, and cardiologists use a wide range of terms for congenital circulatory malformations. Coders must recognize these aliases to ensure accurate code assignment.

🩺 3. Signs & Symptoms

Clinical presentation of congenital circulatory malformations varies markedly by defect type, severity, and whether the lesion is cyanotic or acyanotic. Coders and CDI specialists should recognize these presentations to validate documented diagnoses and identify potential secondary conditions (e.g., pulmonary hypertension, heart failure).

Cyanotic CHD (right-to-left shunting; reduced pulmonary blood flow): Central cyanosis (bluish discoloration of lips, tongue, fingernails), “tet spells” (hypercyanotic episodes in TOF), severe hypoxia on pulse oximetry, poor feeding, tachypnea, clubbing of digits (chronic), polycythemia. Conditions: TOF, TGA, tricuspid atresia, pulmonary atresia, HLHS, TAPVC.

Acyanotic CHD (left-to-right shunting; increased pulmonary blood flow): Pulmonary overcirculation signs—tachypnea, diaphoresis with feeding, poor weight gain, frequent respiratory infections, congestive heart failure (CHF). Systolic murmurs at left sternal border (VSD), fixed split S2 (ASD), continuous machinery murmur (PDA). Conditions: VSD, ASD, AVSD, PDA.

Obstructive lesions: Upper extremity hypertension with diminished or delayed femoral pulses (coarctation of aorta), systolic ejection murmur radiating to neck (aortic stenosis), right ventricular outflow tract gradient (pulmonary stenosis), syncope or exercise intolerance.

Secondary complications: Pulmonary arterial hypertension (I27.21) from chronic left-to-right shunting (Eisenmenger physiology → I27.83), infective endocarditis risk (especially unrepaired VSDs, bicuspid aortic valve), arrhythmias (post-repair TOF → ventricular tachycardia, complete heart block), paradoxical embolism via ASD/PFO, stroke (TIA), developmental delay, exercise intolerance.

🧭 4. Differential Diagnosis

CHD must be distinguished from acquired cardiac conditions and other causes of similar presentations. The following differential diagnoses are relevant for coders and CDI specialists reviewing documentation.

📋 5. Clinical Indicators for Coders/CDI

The following clinical indicators should prompt code assignment, CDI queries, or documentation clarification. Coders should ensure that all documented conditions meeting the definition of a reportable diagnosis are captured.

🦴 6. Anatomy & Pathophysiology

Normal cardiac development: The heart develops from the cardiac crescent during weeks 3–8 of gestation. Key developmental processes include cardiac looping, septation (formation of atrial and ventricular septa), and outflow tract development. Disruption during these critical windows leads to the spectrum of CHD, as detailed by the NIH StatPearls developmental cardiology reference.

Hemodynamic consequences by defect type:

• Left-to-right shunts (VSD, ASD, AVSD, PDA): Oxygenated blood recirculates through the pulmonary vasculature → pulmonary overcirculation → right heart volume overload → pulmonary hypertension if untreated → eventual Eisenmenger syndrome (R→L shunt reversal). VSD produces Qp:Qs ratio >1.5:1 when hemodynamically significant.
• Right-to-left shunts (TOF, TGA, pulmonary atresia, HLHS): Deoxygenated blood enters systemic circulation → central cyanosis → systemic arterial oxygen desaturation. In TOF, infundibular spasm precipitates hypercyanotic “tet spells.”
• Obstructive lesions (coarctation of aorta, aortic stenosis, pulmonary stenosis): Fixed outflow obstruction → pressure overload → ventricular hypertrophy → heart failure if severe or untreated.
• HLHS (Q23.4): Underdevelopment of left-sided structures (aortic valve, mitral valve, left ventricle, ascending aorta) → single-ventricle circulation → systemic output depends on ductal patency; ductal closure at birth is fatal without immediate intervention.
• TGA (Q20.3): Aorta arises from RV, pulmonary artery from LV → two parallel, non-mixing circulations → incompatible with life unless communication exists (ASD, VSD, PDA).
• TAPVC (Q26.2): All four pulmonary veins drain anomalously (to right atrium, coronary sinus, or systemic veins) → obligate R→L shunt through ASD; obstructed TAPVC is a neonatal emergency.

Genetic associations: Approximately 20–30% of CHD cases have an identifiable genetic cause. Key associations include: Trisomy 21 / Down syndrome (Q90.x) → AVSD (40%), ASD, VSD; 22q11.2 deletion / DiGeorge syndrome (Q93.81) → conotruncal defects (TOF, truncus arteriosus, interrupted aortic arch); Marfan syndrome (Q87.410) → aortic dilation/dissection risk; Turner syndrome (Q96.x) → bicuspid aortic valve, coarctation of aorta; Noonan syndrome (Q87.19) → pulmonary stenosis, HCM, per American Heart Association guidelines.

💊 7. Medication Impact / Treatment

Pharmacologic management is used as primary or adjunctive therapy for CHD, and medications documented in the record may serve as clinical indicators for specific conditions. Coders should review the medication reconciliation list as a CDI trigger.

Prostaglandin E1 (alprostadil, PGE1): Maintains ductal patency in duct-dependent lesions (HLHS, TGA, coarctation, pulmonary atresia) prior to surgical intervention. Presence of PGE1 infusion in a neonate strongly indicates critical CHD requiring immediate coding attention.

Diuretics (furosemide, spironolactone, chlorothiazide): Used for congestive heart failure management in CHD with significant L→R shunt (VSD, AVSD, PDA). Document associated heart failure (I50.x) with the underlying CHD code.

ACE inhibitors / ARBs (captopril, enalapril, losartan): Reduce afterload in CHD with ventricular dysfunction or heart failure; used in Marfan syndrome to slow aortic dilation.

Digoxin: Cardiac glycoside used for rate control and inotropic support in CHD-associated heart failure or arrhythmia management.

Beta-blockers (propranolol, atenolol): Propranolol is classic treatment for hypercyanotic tet spells in TOF; also used for arrhythmia management post-repair and in Marfan syndrome.

Endothelin receptor antagonists / PDE5 inhibitors (bosentan, sildenafil): Used for pulmonary arterial hypertension associated with CHD (secondary PAH, I27.21; Eisenmenger syndrome, I27.83). Presence of these medications should trigger query for associated PAH coding.

Indomethacin / Ibuprofen (IV): COX inhibitors used pharmacologically to close PDA in premature neonates. Successful closure results in resolved PDA → code PDA while active; use Z87.74 after confirmed closure in subsequent encounters.

Anticoagulants (warfarin, heparin, DOACs): Used in CHD patients with mechanical valve prostheses, atrial arrhythmias, Fontan palliation, or hypercoagulable states; code underlying indication.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides

📘 8. ICD-10-CM Guidelines (FY2026)

The following guidelines govern assignment of Q20–Q28 codes for FY2026 (effective October 1, 2025), as published in the ICD-10-CM Official Guidelines for Coding and Reporting, FY2026.

Chapter 17 General Guidelines — Congenital Malformations (Q00–Q99)

• Lifelong coding: Codes from Q00–Q99 may be used throughout the life of the patient if the condition is still clinically present (Chapter 17, Section I.C.17). Unlike perinatal codes, Q-codes have no age restriction.
• Sequencing: The congenital defect is the principal diagnosis when the encounter is primarily for the defect itself or its repair. When the encounter is for management of a manifestation (e.g., heart failure, arrhythmia), sequence the manifestation as principal and the underlying CHD as additional diagnosis.
• Corrected conditions: When a congenital malformation has been corrected and is no longer clinically relevant, assign Z87.74 (Personal history of [corrected] congenital malformations of heart and circulatory system) — not the Q-code. Query providers when documentation uses “history of” ambiguously.
• Multiple defects: Code each congenital malformation separately. Combination codes exist for specific syndromes (e.g., TOF at Q21.3 captures all four components); do not code components of a coded combination separately.
• POA (Present on Admission): All congenital malformation codes Q00–Q99 are exempt from POA reporting for inpatient admissions per the CMS POA exempt list, as confirmed by CMS POA guidelines.

Specific FY2026 Coding Notes for Q20–Q28

• ASD expanded subcodes (Q21.1x): FY2026 introduced granular ASD subcategories. Q21.10 = unspecified ASD; Q21.11 = secundum ASD; Q21.12 = patent foramen ovale (PFO); Q21.13 = coronary sinus ASD; Q21.14 = superior sinus venosus ASD; Q21.15 = inferior sinus venosus ASD; Q21.16 = sinus venosus ASD, unspecified; Q21.19 = other specified ASD. Document and query for specificity.
• AVSD expanded subcodes (Q21.2x): Q21.20 = unspecified AVSD; Q21.21 = partial AVSD; Q21.22 = transitional AVSD; Q21.23 = complete AVSD. The distinction between partial and complete AVSD is clinically and surgically significant and should be confirmed via query.
• Bicuspid aortic valve (Q23.81): Newly specified in FY2026 expansion of Q23 subcategory. Previously coded as Q23.0 (if stenosis present) or Q23.8 (other). Assign Q23.81 when bicuspid valve is documented without stenosis or insufficiency as the sole finding.
• Pulmonary hypertension and CHD: When secondary pulmonary arterial hypertension (I27.21) is caused by congenital heart disease, code I27.21 first, then add the CHD code (Q20–Q28). If Eisenmenger syndrome develops, assign I27.83 + the underlying structural defect Q-code.
• Tetralogy of Fallot (Q21.3): This is a combination code encompassing all four components (VSD, pulmonary stenosis/atresia, overriding aorta, RVH). Do not code the components separately. Assign Q21.3 regardless of repair status as long as the condition is clinically active, per AAPC Cardiology Coding Alert guidance.
• Associated genetic syndromes: When CHD is associated with Down syndrome (Q90.x), DiGeorge/22q11.2 deletion (Q93.81), Marfan syndrome (Q87.410), Turner syndrome (Q96.x), or other genetic syndrome, code both the syndrome and the specific cardiac defect.
• HLHS palliation status: After Norwood stage 1, code Q23.4 (HLHS) for the underlying condition and appropriate Z-codes for device/anastomosis status. Fontan circulation status is captured via Z95.x and procedure codes.

🔢 9. ICD-10-CM Code Set (FY2026)

The following table presents the primary FY2026 ICD-10-CM codes for congenital circulatory malformations, verified against the CMS FY2026 ICD-10-CM tabular list and the Q20–Q28 code range. MS-DRG assignments reference MS-DRG v43.1 (CMS).

🔎 10. Indexing

The ICD-10-CM Alphabetic Index provides multiple entry points for congenital circulatory malformations. Key index terms and their code pathways:

• Defect → Heart → congenital → septal → ventricular (Q21.0); atrial → secundum (Q21.11)
• Tetralogy of Fallot → Q21.3
• Transposition → great arteries (vessels) → Q20.3; complete → Q20.3
• Hypoplastic → left heart (syndrome) → Q23.4
• Patent → ductus arteriosus → Q25.0
• Coarctation → aorta (preductal) (postductal) → Q25.1
• Anomaly → pulmonary venous connection (total) (partial) → Q26.2 / Q26.3
• Ebstein’s anomaly → Q22.5
• Truncus arteriosus → Q20.0
• Syndrome → DiGeorge → Q93.81; Down → Q90.x; Eisenmenger → I27.83
• Valve → aortic → congenital → bicuspid → Q23.81; stenosis → Q23.0
• History of (personal) → malformation → heart (corrected) → Z87.74

🏥 11. CPT (2026)

CPT codes for CHD surgical intervention are complex and high-value. The following table presents key 2026 CPT codes, verified against AAPC CPT code range resources and ACC 2026 CPT updates.

🧾 12. HCPCS (2026)

The following HCPCS Level II codes are relevant for supplies, devices, and services used in the management of congenital circulatory malformations, per CMS HCPCS 2026.

📚 13. AHA Coding Clinic (Recent Guidance)

The AHA Coding Clinic has issued several advisories relevant to congenital circulatory malformations. Coders should review and apply the following guidance:

• Coding Clinic Q2 2024 — ASD Specificity (FY2024/FY2025 expansion): With the introduction of expanded ASD subcategories (Q21.11–Q21.19), Coding Clinic confirmed that coders should query for the specific type of ASD when documentation is ambiguous. Secundum vs. sinus venosus vs. PFO distinctions carry distinct clinical and hemodynamic significance. Review echo reports for terminology.
• Coding Clinic Q3 2023 — AVSD partial vs. complete: Coding Clinic guidance addressed documentation requirements to distinguish partial AVSD (Q21.21) from complete AVSD (Q21.23). Partial AVSD has a cleft mitral valve and an ostium primum ASD without a VSD component. Complete AVSD has a common AV valve, primum ASD, and inlet VSD. These distinctions affect surgical complexity and DRG assignment.
• Coding Clinic Q1 2022 — History of CHD vs. active CHD: Clarified that “history of” VSD repair requires provider clarification. If residual VSD exists or the patient has ongoing cardiac effects from the defect, the Q-code (Q21.0) should be reported—not Z87.74. This is one of the most common CDI query opportunities in adult CHD patients.
• Coding Clinic Q4 2021 — Eisenmenger syndrome: Confirmed that I27.83 (Eisenmenger syndrome) should be coded with an additional code for the underlying structural defect. The Q-code should not be omitted even though the shunt may have reversed direction. Both codes contribute to RAF and DRG complexity.
• Coding Clinic Q2 2020 — TOF Post-Repair: Affirmed that Q21.3 remains appropriate for patients with repaired TOF who have ongoing clinical manifestations (e.g., pulmonary regurgitation, RV dilation, arrhythmia). Providers documenting “repaired TOF with complications” should be queried for specificity regarding current manifestations to support additional coding (e.g., I37.1 for pulmonary valve regurgitation, I47.2 for ventricular tachycardia).

💰 14. HCC / Risk Adjustment (v28)

Under the CMS-HCC Model Version 28 (effective CY2024–2026), congenital circulatory malformations map to specific HCC categories that drive risk adjustment factor (RAF) scores for Medicare Advantage plans. Accurate coding of CHD and associated conditions is critical to RAF capture.

Key v28 HCC principles for CHD: HCC v28 emphasizes documentation specificity. The model rewards precise identification of the structural defect, its current clinical status, and associated comorbidities. Providers should document annually whether CHD is still present and clinically relevant — a critical requirement for annual RAF recapture in Medicare Advantage populations, as noted in Notable Health’s V28 transition analysis. Adults with CHD, particularly those who have undergone surgical palliation, carry significant resource utilization burdens that should be fully captured through comprehensive HCC coding.

✍️ 15. CDI Query Templates

All queries below comply with AHIMA and ACDIS compliant query standards: non-leading, multiple choice, clinically supported, and purpose-stated.

🧑‍⚕️ 16. Treatments (Clinical)

Treatment for congenital circulatory malformations depends on defect type, severity, associated lesions, and patient age/condition. Documentation of treatment approach informs coding, DRG assignment, and clinical validation.

Interventional (Catheter-Based)

• Transcatheter ASD/VSD closure: Percutaneous device closure (e.g., Amplatzer Septal Occluder) for secundum ASD and selected VSDs. Less invasive than open surgery; increasingly first-line for amenable defects. CPT 93580 (transcatheter ASD closure), 93581 (VSD closure).
• Balloon valvuloplasty: For congenital pulmonary stenosis (Q22.1) or aortic stenosis (Q23.0); dilates stenotic valve via balloon catheter. CPT 92990 (pulmonary), 92986 (aortic).
• Transcatheter pulmonary valve replacement (TPVI): Melody or Sapien XT valve delivered via catheter into RV outflow tract conduit in post-TOF repair or pulmonary stenosis patients. CPT 33477.
• Coarctation stenting: Endovascular stent placement in adolescents/adults with CoA; balloon angioplasty in neonates (Q25.1).
• Blade/balloon atrial septostomy (Rashkind procedure): Emergency palliation for TGA or HLHS to create/enlarge ASD for mixing. CPT 92992 (balloon), 92993 (blade).

Surgical (Open Heart)

• Norwood procedure (Stage 1): Neonatal palliation for HLHS (Q23.4). Reconstructs neo-aorta from main pulmonary artery + ascending aorta; creates systemic-to-pulmonary shunt (Blalock-Taussig-Thomas shunt or Sano shunt). CPT 33619.
• Bidirectional Glenn / Stage 2: Superior cavopulmonary anastomosis (SVC to pulmonary artery). CPT 33766, 33767, or component of 33622.
• Fontan completion (Stage 3): Total cavopulmonary connection (TCPC); inferior vena cava to pulmonary artery via extracardiac conduit or lateral tunnel. CPT 33615.
• Arterial switch operation (Jatene): Definitive repair of TGA (Q20.3); aorta and pulmonary artery transected and switched to appropriate ventricles; coronary reimplantation required. CPT 33782.
• TOF complete repair: VSD patch closure + RVOT reconstruction (resection of infundibular stenosis ± transannular patch). CPT 33692, 33694. Definitive repair typically performed at 3–6 months of age.
• TAPVC repair: Anastomosis of anomalous pulmonary venous confluence to left atrium; closure of ASD. CPT 33730. Obstructed form requires emergent neonatal surgery.
• Coarctation repair: Resection and end-to-end anastomosis, patch aortoplasty, or subclavian flap repair. CPT 33840, 33845, 33851, 33852. Endovascular stenting for adolescents/adults.

Post-Repair Surveillance and Long-Term Management

Adults with congenital heart disease (ACHD) require lifelong subspecialty follow-up. The AHA/ACC 2018 ACHD Guidelines recommend dedicated ACHD center follow-up for complex lesions. Long-term issues include pulmonary valve dysfunction (post-TOF), Fontan circuit complications (protein-losing enteropathy, atrial arrhythmia, Fontan failure), aortopathy (BAV, Marfan, CoA), endocarditis prophylaxis (high-risk unrepaired or residual defects), and arrhythmia surveillance (24-hour Holter, ICD placement in selected patients).

🎓 17. Patient Education / Summary

What is congenital heart disease? Congenital heart disease (CHD) means the heart or the blood vessels near the heart did not form normally before birth. The word “congenital” means present at birth. CHD is the most common type of birth defect in the United States, affecting about 1 in 100 babies born each year, according to the CDC.

Types of heart defects: There are many types of CHD. Some, like a small hole in the wall between the heart’s chambers (ventricular septal defect or atrial septal defect), are mild and may close on their own. Others, such as tetralogy of Fallot, hypoplastic left heart syndrome, or transposition of the great arteries, are more complex and require surgery or other procedures, often shortly after birth.

Symptoms to know: CHD may cause bluish skin or lips (cyanosis), fast breathing, poor feeding, weight gain problems in infants, fatigue, or fainting during exercise. Some forms of CHD cause no symptoms at all and may only be discovered by a doctor’s examination or tests.

How is CHD treated? Many CHD conditions are treated with surgery, catheter procedures (minimally invasive), or medicines to manage symptoms. Some patients need multiple surgeries over their lifetime. Advances in medical care mean that most children born with CHD now live into adulthood.

Lifelong care is important: Even after treatment, people with CHD need regular follow-up with a heart specialist (cardiologist), preferably one specializing in adult congenital heart disease (ACHD). Regular check-ups help catch any problems early, manage medications, and monitor heart function over time. The American Heart Association recommends lifelong care for anyone born with a significant heart defect.

Genetic testing: Some CHDs run in families or are linked to chromosomal conditions like Down syndrome or DiGeorge syndrome. Genetic counseling may be recommended for patients with CHD or family members of affected individuals.

Why accurate diagnosis documentation matters: Complete and specific documentation of your CHD diagnosis helps your care team coordinate treatment, ensures insurance coverage for necessary services, supports long-term care planning, and helps track your health over time. If you have a repaired or managed heart defect, it is important that your doctors document its ongoing status each year to ensure your health record accurately reflects your heart condition.

About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2026 ICD-10-CM (effective October 1, 2025). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)